Orexo AB (publ) ORXOF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • SE • USD

SharesGrow Score

18/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Orexo AB (publ) (ORXOF) reported total assets of $1.3B and total liabilities of $810.16M for fiscal year 2025, resulting in total equity of $489.37M.

The company held $910.11M in cash and short-term investments. Total debt stood at $490.97M, with net debt of $-419.15M. The Debt-to-Equity (D/E) ratio was 1 (moderate).

Current ratio is 3.7, indicating strong short-term liquidity. Interest coverage is -6.9x (weak).

Criteria supported by this page:

HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
MOAT (0/100) — Total assets $1.3B and equity $489.37M support the company's competitive scale

Overall SharesGrow Score: 17/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

18/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

HEALTH

50/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

0/100

→ Income

✗

GROWTH

30/100

→ Income

✗

INCOME

10/100

→ Income

Orexo AB (publ) Balance Sheet History

Metric	FY2025	FY2024	FY2023	FY2022
Total Assets	$1.3B	$594.8M	$786.6M	$1.11B
Total Liabilities	$810.16M	$721.1M	$727.7M	$915.1M
Total Debt	$490.97M	$476M	$473.8M	$539.6M
Cash & Investments	$910.11M	$123.3M	$171M	$351.8M
Total Stockholders Equity	$489.37M	$-126.3M	$58.9M	$193.9M